Judges Scientific confirms that, as at 1 November 2019, the total issued share capital has increased to 6,222,291 ordinary shares of 5p each ("Ordinary Share").
There are no Ordinary Shares held in treasury. Each Ordinary Share carries voting rights on the basis of one vote per Ordinary Share. Therefore, the total number of voting rights in Judges Scientific is 6,222,291 Ordinary Shares.
The above figure may be used by shareholders as the denominator for calculations to determine if they have a notifiable interest in Judges Scientific under the Disclosure and Transparency Rules, or if such interest has changed.
- Ends -
David Cicurel, CEO
Brad Ormsby, Group FD
Tel: +44 (0) 203 829 6970
Shore Capital (Nominated Adviser & Joint Broker)
Tel: +44 (0) 20 7408 4090
Liberum (Joint Broker)
Alma (Financial Public Relations)
Tel: +44 (0) 20 3100 2222
Tel: +44 (0) 20 3865 9886
Notes to editors:
Judges Scientific plc (AIM: JDG), is a group involved in the buy and build of scientific instrument businesses. The Group currently consists of 16 businesses acquired since it was re-admitted to AIM in 2005.
The acquired companies are primarily UK-based with products sold worldwide to a diverse range of markets including: higher education institutions, the scientific communities, manufacturers and regulatory authorities. The UK is a recognised centre of excellence for scientific instruments. The Group has received five Queens' awards for innovation and export.
Judges Scientific maintains a policy to selectively acquire businesses that generate sustainable profits and cash. Shareholder returns are created through the reduction of debt, payment of increasing dividends and through organic growth which the Group encourages by creating an environment for businesses to thrive in, with support and advice for entity management teams.
The Group's companies predominantly operate in global niche markets, with long term growth fundamentals and resilient margins.
For further information, please visit www.judges.uk.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...